CN105169009A - Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza Download PDFInfo
- Publication number
- CN105169009A CN105169009A CN201510540460.8A CN201510540460A CN105169009A CN 105169009 A CN105169009 A CN 105169009A CN 201510540460 A CN201510540460 A CN 201510540460A CN 105169009 A CN105169009 A CN 105169009A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- chinese medicine
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 206010022000 influenza Diseases 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000003612 virological effect Effects 0.000 title claims abstract description 22
- 244000025254 Cannabis sativa Species 0.000 claims description 35
- 241000331777 Arisaema balansae Species 0.000 claims description 21
- 241000953577 Cyathocline Species 0.000 claims description 21
- 241000628997 Flos Species 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 14
- 239000002699 waste material Substances 0.000 abstract description 2
- 241000772998 Arthraxon Species 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 240000004082 Bidens tripartita Species 0.000 abstract 1
- 235000000621 Bidens tripartita Nutrition 0.000 abstract 1
- 244000003240 Caesalpinia gilliesii Species 0.000 abstract 1
- 235000014161 Caesalpinia gilliesii Nutrition 0.000 abstract 1
- 241001635617 Canscora Species 0.000 abstract 1
- 240000002373 Ficus pumila Species 0.000 abstract 1
- 235000006718 Ficus pumila Nutrition 0.000 abstract 1
- 244000214240 Galinsoga parviflora Species 0.000 abstract 1
- 235000018914 Galinsoga parviflora Nutrition 0.000 abstract 1
- 240000007677 Heynea trijuga Species 0.000 abstract 1
- 235000003956 Luffa Nutrition 0.000 abstract 1
- 244000050983 Luffa operculata Species 0.000 abstract 1
- 244000174681 Michelia champaca Species 0.000 abstract 1
- 240000007817 Olea europaea Species 0.000 abstract 1
- 241001660931 Salvia prionitis Species 0.000 abstract 1
- 235000015558 Salvia prionitis Nutrition 0.000 abstract 1
- 241000594377 Tarenna Species 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 244000112814 pipewort Species 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 35
- 239000007788 liquid Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000002481 ethanol extraction Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000004570 mortar (masonry) Substances 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 201000009240 nasopharyngitis Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a traditional Chinese medicine composition in the preparation of medicine for treating viral influenza. The effective constituents of the traditional Chinese medicine composition are prepared by, by weight, 52-76 parts of asarum, 50-74 parts of whiteflower tarenna leaf or fruit, 48-72 parts of galinsoga parviflora, 45-70 parts of bidens tripartita, 42-68 parts of hispid arthraxon, 40-65 parts of purple cathoclines, 35-60 parts of olive, 35-60 parts of radix angelicae dahuricae, 30-55 parts of salvia prionitis, 25-45 parts of trichilia connaroides, 25-40 parts of champac root, 20-35 parts of Canscora melastomacea Hand.-Mazz., 20-35 parts of mysorethorn root, 15-30 parts of ficus pumila, 12-24 parts of pipewort and 8-20 parts of luffa root. A new treatment purpose of the traditional Chinese medicine composition is provided, the clinical application range of the traditional Chinese medicine composition is expanded, and waste of good medicine resources is avoided.
Description
Technical field
The present invention relates to field of medicaments, the specifically application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine.
Background technology
Influenza is caused by virus attack upper respiratory tract, and disease main manifestations is paroxysmal hyperpyrexia, myalgia, headache and strong sense of discomfort, often with cough, have sore throat and the symptom such as rhinitis.Influenza can be propagated by rapid spread in epidemic season, takes antibacterials not only invalid, can also cause virus variation, bacterial resistance, and produces adverse effect etc.Therefore inappropriate medication not only can delay diagnosis and treatment, and heavy financial burden is brought to hospital and patient, meanwhile, influenza can cause multiple complications, especially child and old man ill, multiple internal disease can be caused, as various problems such as pneumonia, diabetes, cancer, nephropathy or heart diseases, caused the great attention of people, China is influenza prone areas, almost all can have the outburst of influenza local every year, say thus, the drug development for the treatment of viral influenza curative effect good is particularly important in China.
Chinese medicine is owing to having unique theoretical basis, advantage that toxic and side effects is little, huge advantage is shown in treatment of influenza, it can overcome the shortcoming that Western medicine index is not effected a permanent cure, while playing powerful antivirus action, conditioner body immunity function on the whole, thorough eradicate influenza virus in vivo residual, and produce relatively lasting antibody and support and antivirally again to attack.
Prescription of the present invention is after December in 2014 discloses as the medicine for the treatment of acute nasopharyngitis in the application of Chinese patent 201410483776.3 on the 10th, we find that in a large amount of clinical practice the party is except curing mainly function, also there is the good efficacy for the treatment of viral influenza, not only onset is rapid, curative effect lasting, and untoward reaction is few.In order to develop the new clinical application of this medicine further, reducing the wasting of resources of medicine, this medicine having been carried out a series of drug effect and dosage form research, for clinical practice is taken a firm foundation widely.
Summary of the invention
The object of the present invention is to provide a kind of new therapeutic use of Chinese medicine composition, the specifically application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine.
For achieving the above object, the invention provides following technical scheme:
The application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 52-76 part, Folium seu Fructus Tarennae 50-74 part, Herba galinsogae parviflorae 48-72 part, Herba Bidentis Tripartitae 45-70 part, Herba Arthraxonis Hispidi 42-68 part, Herba Cyathoclines purpureae 40-65 part, Fructus Canarii albi 35-60 part, Radix Angelicae Dahuricae 35-60 part, Arisaema balansae Engl. grass 30-55 part, Radix heyneae trijugae 25-45 part, Radix micheliae champacae 25-40 part, Luo Xing grass 20-35 part, Radix Caesalpiniae Radicis 20-35 part, Fructus Fici Pumilae 15-30 part, Flos Eriocauli 12-24 part and Radix Luffae 8-20 part.Chinese medicine composition of the present invention has effect of heat-clearing and toxic substances removing, anti-inflammation detumescence, relieving sore throat and pain, clinical only for the treatment to acute nasopharyngitis (containing symptoms such as infectious rhinitis, pharyngalgia, mouth breathing, oropharynx foreign matters) at present.
As the further scheme of the present invention: according to parts by weight, the raw material making this drug composition active component is: Herba Asari 70 parts, Folium seu Fructus Tarennae 68 parts, Herba galinsogae parviflorae 66 parts, Herba Bidentis Tripartitae 64 parts, Herba Arthraxonis Hispidi 61 parts, Herba Cyathoclines purpureae 58 parts, Fructus Canarii albi 54 parts, the Radix Angelicae Dahuricae 54 parts, Arisaema balansae Engl. grass 48 parts, Radix heyneae trijugae 40 parts, Radix micheliae champacae 36 parts, Luo Xing grass 30 parts, Radix Caesalpiniae Radicis 30 parts, Fructus Fici Pumilae 26 parts, Flos Eriocauli 21 parts and Radix Luffae 17 parts.
As the further scheme of the present invention: according to parts by weight, the raw material making this drug composition active component is: Herba Asari 64 parts, Folium seu Fructus Tarennae 62 parts, Herba galinsogae parviflorae 60 parts, Herba Bidentis Tripartitae 58 parts, Herba Arthraxonis Hispidi 54 parts, Herba Cyathoclines purpureae 52 parts, Fructus Canarii albi 48 parts, the Radix Angelicae Dahuricae 48 parts, Arisaema balansae Engl. grass 42 parts, Radix heyneae trijugae 35 parts, Radix micheliae champacae 32 parts, Luo Xing grass 26 parts, Radix Caesalpiniae Radicis 26 parts, Fructus Fici Pumilae 22 parts, Flos Eriocauli 18 parts and Radix Luffae 14 parts.
As the further scheme of the present invention: according to parts by weight, the raw material making this drug composition active component is: Herba Asari 58 parts, Folium seu Fructus Tarennae 56 parts, Herba galinsogae parviflorae 54 parts, Herba Bidentis Tripartitae 52 parts, Herba Arthraxonis Hispidi 48 parts, Herba Cyathoclines purpureae 46 parts, Fructus Canarii albi 42 parts, the Radix Angelicae Dahuricae 42 parts, Arisaema balansae Engl. grass 34 parts, Radix heyneae trijugae 30 parts, Radix micheliae champacae 28 parts, Luo Xing grass 22 parts, Radix Caesalpiniae Radicis 22 parts, Fructus Fici Pumilae 18 parts, Flos Eriocauli 15 parts and Radix Luffae 11 parts.
As the further scheme of the present invention: described Chinese medicine composition contains pharmaceutically acceptable oral formulations adjuvant.
The preparation method of Chinese medicine composition of the present invention, comprises the following steps:
(1) by adding the water of 8 times amount after Herba Asari, Folium seu Fructus Tarennae, Herba galinsogae parviflorae, Herba Arthraxonis Hispidi, Herba Cyathoclines purpureae, the Radix Angelicae Dahuricae, Luo Xingcao, Radix Caesalpiniae Radicis, Fructus Fici Pumilae and Flos Eriocauli mixing, extracting 2-3 hour, filtering, taking liquid; In remaining residue, add the water of 6 times amount again, extract 1-2 hour, filter, taking liquid; Merge twice medicinal liquid, be condensed into the thick paste of relative density 1.10-1.15 at 60 DEG C, drying under reduced pressure;
(2) Herba Bidentis Tripartitae, Arisaema balansae Engl. grass and Radix Luffae are put in pot to add with slow fire and propagandize hotly to surperficial buff, pulverize after fried dry, ground 200 order fine powders into powder, for subsequent use;
(3) get Fructus Canarii albi Fructus Canarii, add in fire and calcine, be placed in mortar and grind into powder, cross 180 order fine powders, for subsequent use;
(4) Radix heyneae trijugae and Radix micheliae champacae are added 10 times amount volumetric concentration 70% ethanol extraction three times, each 3 hours, filter, merging filtrate, placement is spent the night, and reclaiming ethanol and being concentrated into 60 DEG C of relative densities is that the dope of 1.12-1.15 is for subsequent use;
(5) dope mixing fine powder obtained to obtained for step (1) thick paste, step (2) and step (3) and step (4) obtained, is the active component of Chinese medicine composition of the present invention.
The preparation method of Chinese medicine composition of the present invention is suitable for commercial Application.Described Chinese medicine composition comprises the various oral formulations be pharmaceutically suitable for, such as granule, capsule, tablet.The method that the present invention prepares various oral formulations is pharmaceutically common method, as Conventional compression, granulation, encapsulated etc.Instructions of taking: oral, every day, potion, point morning, evening twice, each containing crude drug amount 100-125g.
The present invention finds that in a large amount of clinical practices it has the effect of significant treatment viral influenza, and therefore, we have carried out more deep research to the novelty teabag that the present invention treats viral influenza, and existing by main effect experiment, details are as follows:
Experiment 1: In vitro antibacterial test of the present invention
1. the toxicity test of pair Hep-2 cultured cell
1.1 trial drug preparations:
(1) according to parts by weight, take Herba Asari 64 parts, Folium seu Fructus Tarennae 62 parts, Herba galinsogae parviflorae 60 parts, Herba Bidentis Tripartitae 58 parts, Herba Arthraxonis Hispidi 54 parts, Herba Cyathoclines purpureae 52 parts, Fructus Canarii albi 48 parts, the Radix Angelicae Dahuricae 48 parts, Arisaema balansae Engl. grass 42 parts, Radix heyneae trijugae 35 parts, Radix micheliae champacae 32 parts, Luo Xing grass 26 parts, Radix Caesalpiniae Radicis 26 parts, Fructus Fici Pumilae 22 parts, Flos Eriocauli 18 parts and Radix Luffae 14 parts, for subsequent use; By adding the water of 8 times amount after Herba Asari, Folium seu Fructus Tarennae, Herba galinsogae parviflorae, Herba Arthraxonis Hispidi, Herba Cyathoclines purpureae, the Radix Angelicae Dahuricae, Luo Xingcao, Radix Caesalpiniae Radicis, Fructus Fici Pumilae and Flos Eriocauli mixing, extracting 2-3 hour, filtering, taking liquid; In remaining residue, add the water of 6 times amount again, extract 1-2 hour, filter, taking liquid; Merge twice medicinal liquid, be condensed into the thick paste of relative density 1.10-1.15 at 60 DEG C, drying under reduced pressure;
(2) Herba Bidentis Tripartitae, Arisaema balansae Engl. grass and Radix Luffae are put in pot to add with slow fire and propagandize hotly to surperficial buff, pulverize after fried dry, ground 200 order fine powders into powder, for subsequent use;
(3) get Fructus Canarii albi Fructus Canarii, add in fire and calcine, be placed in mortar and grind into powder, cross 180 order fine powders, for subsequent use;
(4) Radix heyneae trijugae and Radix micheliae champacae are added 10 times amount volumetric concentration 70% ethanol extraction three times, each 3 hours, filter, merging filtrate, placement is spent the night, and reclaiming ethanol and being concentrated into 60 DEG C of relative densities is that the dope of 1.12-1.15 is for subsequent use;
(5) fine powder obtained to obtained for step (1) thick paste, step (2) and step (3) and the obtained dope of step (4) are mixed, adding distilled water, to be configured to debita spissitudo for subsequent use.
Arrived by Experimental Observation On Toxicity, the medicinal liquid cell growth of 0.60mg/mL, 1.20mg/mL of the present invention two kinds of concentration has no significant effect, therefore gets these two kinds of concentration liquids as antivirus test medication.
1.2 impacts on pathological changes caused by virus effect
Tested virus: parainfluenza-1, RSV, CoxB
4, CoxB
5, CoxB
6, ADV
3, ADV
7, HSV-I, HSV-II.
The results detailed in Table 1.
Table 1 the present invention is on the impact of pathological changes caused by virus effect
Table 1 result shows, and high dose group of the present invention (1.20mg/mL) all has stronger inhibitory action to 9 kinds of viruses, and low dose group (0.6mg/ml) has inhibitory action to 8 kinds of viruses, and high dose group inhibition strength compares with positive controls virazole, to CoxB
5, CoxB
6, cytopathy caused by HSV-II Strain has more high inhibition rate, other Strain inhibition is suitable, shows that antivirus action of the present invention is more extensive.
The effect of infected by influenza in 1.3 bodies of the present invention
1.3.1 the present invention to the exercising result of mouse influenza virus pneumonia in table 2.Wherein, suppression ratio (%)=[(virus control group-X)/virus control group] × 100%.
Table 2 the present invention is to the influence of pulmonary lesion caused by mouse infection influenza virus
Compare with Normal group, * * P<0.01; Compare with virus control group, #P<0.05, ##P<0.0l.
Shown by table 2 result, virus control group obviously increases Lung Exponent value (P<0.01), after giving Drug therapy, the present invention fills with the dosage of 2.5g crude drug/kg, 5.0g crude drug/kg and feeds mice, obviously can reduce the Lung Exponent value of infecting mouse, because influenza infection can cause pneumonia, cause the infiltration of inflammation part inflammatory cell, ooze out, pulmonary's weight is increased, and Lung Exponent value raises.The size of lung weight reflects the pulmonary inflammatory order of severity, the present invention significantly can alleviate the degree of inflammation (P<0.05 or P<0.01) caused by influenza virus, and wherein high dose group of the present invention compares therapeutic equivalence with virazole group.
1.3.2 the present invention is to the influence of proliferation of influenza virus amount in mouse lung
The results are shown in Table 3.
Table 3 the present invention is to the influence of proliferation of influenza virus amount in mouse lung
Compare with virus control group, #P<0.05, ##P<0.0l.Shown by table 3 result, the present invention is low, high dose group all has obvious inhibitory action (P<0.05 or P<0.01) to proliferation of influenza virus amount in mouse lung.
Above test shows, the present invention has good antivirus action, for clinical practice is taken a firm foundation.In addition, we also to carry out antibacterial, antiinflammatory, immunological enhancement, antiallergic, the tests such as cough-relieving, result shows, the present invention can suppress staphylococcus aureus, A group streptococcus, Pseudomonas aeruginosa, the growth of the strains such as e coil k 1 pneumonia, improve the phagocytic function of Turnover of Mouse Peritoneal Macrophages, suppress the rat toes swelling caused by 5-HF, suppress the extensively antiinflammatory action such as histamine phosphate's induced mice capillary permeability increase and the subcutaneous experimental chronic granuloma of rat back caused by agar, the anti-allergic effects such as the contraction of sensitized guinea pig isolated ileal rings anaphylaxis and the passive cutaneous anaphylaxis, PCA of Cavia porcellus xenogenesis can also be suppressed, significantly can also reduce the cough incidence that Cavia porcellus mechanical stimulus causes in heavy dose of situation simultaneously.These pharmacological evaluation are material bases that the present invention is used for the treatment of viral influenza.
Compared with prior art, the invention has the beneficial effects as follows:
1, this traditional Chinese medicine composition for treating viral influenza has no side effect, and it is low to have price, is easy to by advantages such as patient accept;
2, this Chinese medicine composition abundant raw materials, preparation technology is simple, environmentally friendly, has good application prospect in treatment viral influenza;
3, invention increases the clinical application range of this Chinese medicine composition, effectively avoid the waste of good drug resource.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, be clearly and completely described the technical scheme in the embodiment of the present invention, obviously, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, the application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 76 parts, Folium seu Fructus Tarennae 74 parts, Herba galinsogae parviflorae 72 parts, Herba Bidentis Tripartitae 70 parts, Herba Arthraxonis Hispidi 68 parts, Herba Cyathoclines purpureae 65 parts, Fructus Canarii albi 60 parts, the Radix Angelicae Dahuricae 60 parts, Arisaema balansae Engl. grass 55 parts, Radix heyneae trijugae 45 parts, Radix micheliae champacae 40 parts, Luo Xing grass 35 parts, Radix Caesalpiniae Radicis 35 parts, Fructus Fici Pumilae 30 parts, Flos Eriocauli 24 parts and Radix Luffae 20 parts.
The preparation method of described Chinese medicine composition, comprises the following steps:
(1) by adding the water of 8 times amount after Herba Asari, Folium seu Fructus Tarennae, Herba galinsogae parviflorae, Herba Arthraxonis Hispidi, Herba Cyathoclines purpureae, the Radix Angelicae Dahuricae, Luo Xingcao, Radix Caesalpiniae Radicis, Fructus Fici Pumilae and Flos Eriocauli mixing, extracting 3 hours, filtering, taking liquid; In remaining residue, add the water of 6 times amount again, extract 1 hour, filter, taking liquid; Merge twice medicinal liquid, be condensed into the thick paste of relative density 1.10-1.15 at 60 DEG C, drying under reduced pressure;
(2) Herba Bidentis Tripartitae, Arisaema balansae Engl. grass and Radix Luffae are put in pot to add with slow fire and propagandize hotly to surperficial buff, pulverize after fried dry, ground 200 order fine powders into powder, for subsequent use;
(3) get Fructus Canarii albi Fructus Canarii, add in fire and calcine, be placed in mortar and grind into powder, cross 180 order fine powders, for subsequent use;
(4) Radix heyneae trijugae and Radix micheliae champacae are added 10 times amount volumetric concentration 70% ethanol extraction three times, each 3 hours, filter, merging filtrate, placement is spent the night, and reclaiming ethanol and being concentrated into 60 DEG C of relative densities is that the dope of 1.12-1.15 is for subsequent use;
(5) dope mixing fine powder obtained to obtained for step (1) thick paste, step (2) and step (3) and step (4) obtained, makes tablet, is the active component of Chinese medicine composition of the present invention.
Embodiment 2
In the embodiment of the present invention, the application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 70 parts, Folium seu Fructus Tarennae 68 parts, Herba galinsogae parviflorae 66 parts, Herba Bidentis Tripartitae 64 parts, Herba Arthraxonis Hispidi 61 parts, Herba Cyathoclines purpureae 58 parts, Fructus Canarii albi 54 parts, the Radix Angelicae Dahuricae 54 parts, Arisaema balansae Engl. grass 48 parts, Radix heyneae trijugae 40 parts, Radix micheliae champacae 36 parts, Luo Xing grass 30 parts, Radix Caesalpiniae Radicis 30 parts, Fructus Fici Pumilae 26 parts, Flos Eriocauli 21 parts and Radix Luffae 17 parts.
The preparation method of described Chinese medicine composition, comprises the following steps:
(1) by adding the water of 8 times amount after Herba Asari, Folium seu Fructus Tarennae, Herba galinsogae parviflorae, Herba Arthraxonis Hispidi, Herba Cyathoclines purpureae, the Radix Angelicae Dahuricae, Luo Xingcao, Radix Caesalpiniae Radicis, Fructus Fici Pumilae and Flos Eriocauli mixing, extracting 2 hours, filtering, taking liquid; In remaining residue, add the water of 6 times amount again, extract 2 hours, filter, taking liquid; Merge twice medicinal liquid, be condensed into the thick paste of relative density 1.10-1.15 at 60 DEG C, drying under reduced pressure;
(2) Herba Bidentis Tripartitae, Arisaema balansae Engl. grass and Radix Luffae are put in pot to add with slow fire and propagandize hotly to surperficial buff, pulverize after fried dry, ground 200 order fine powders into powder, for subsequent use;
(3) get Fructus Canarii albi Fructus Canarii, add in fire and calcine, be placed in mortar and grind into powder, cross 180 order fine powders, for subsequent use;
(4) Radix heyneae trijugae and Radix micheliae champacae are added 10 times amount volumetric concentration 70% ethanol extraction three times, each 3 hours, filter, merging filtrate, placement is spent the night, and reclaiming ethanol and being concentrated into 60 DEG C of relative densities is that the dope of 1.12-1.15 is for subsequent use;
(5) dope mixing fine powder obtained to obtained for step (1) thick paste, step (2) and step (3) and step (4) obtained, makes granule, is the active component of Chinese medicine composition of the present invention.
Embodiment 3
In the embodiment of the present invention, the application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 64 parts, Folium seu Fructus Tarennae 62 parts, Herba galinsogae parviflorae 60 parts, Herba Bidentis Tripartitae 58 parts, Herba Arthraxonis Hispidi 54 parts, Herba Cyathoclines purpureae 52 parts, Fructus Canarii albi 48 parts, the Radix Angelicae Dahuricae 48 parts, Arisaema balansae Engl. grass 42 parts, Radix heyneae trijugae 35 parts, Radix micheliae champacae 32 parts, Luo Xing grass 26 parts, Radix Caesalpiniae Radicis 26 parts, Fructus Fici Pumilae 22 parts, Flos Eriocauli 18 parts and Radix Luffae 14 parts.
The preparation method of described Chinese medicine composition, comprises the following steps:
(1) by adding the water of 8 times amount after Herba Asari, Folium seu Fructus Tarennae, Herba galinsogae parviflorae, Herba Arthraxonis Hispidi, Herba Cyathoclines purpureae, the Radix Angelicae Dahuricae, Luo Xingcao, Radix Caesalpiniae Radicis, Fructus Fici Pumilae and Flos Eriocauli mixing, extracting 3 hours, filtering, taking liquid; In remaining residue, add the water of 6 times amount again, extract 2 hours, filter, taking liquid; Merge twice medicinal liquid, be condensed into the thick paste of relative density 1.10-1.15 at 60 DEG C, drying under reduced pressure;
(2) Herba Bidentis Tripartitae, Arisaema balansae Engl. grass and Radix Luffae are put in pot to add with slow fire and propagandize hotly to surperficial buff, pulverize after fried dry, ground 200 order fine powders into powder, for subsequent use;
(3) get Fructus Canarii albi Fructus Canarii, add in fire and calcine, be placed in mortar and grind into powder, cross 180 order fine powders, for subsequent use;
(4) Radix heyneae trijugae and Radix micheliae champacae are added 10 times amount volumetric concentration 70% ethanol extraction three times, each 3 hours, filter, merging filtrate, placement is spent the night, and reclaiming ethanol and being concentrated into 60 DEG C of relative densities is that the dope of 1.12-1.15 is for subsequent use;
(5) dope mixing fine powder obtained to obtained for step (1) thick paste, step (2) and step (3) and step (4) obtained, makes tablet, is the active component of Chinese medicine composition of the present invention.
Embodiment 4
In the embodiment of the present invention, the application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 58 parts, Folium seu Fructus Tarennae 56 parts, Herba galinsogae parviflorae 54 parts, Herba Bidentis Tripartitae 52 parts, Herba Arthraxonis Hispidi 48 parts, Herba Cyathoclines purpureae 46 parts, Fructus Canarii albi 42 parts, the Radix Angelicae Dahuricae 42 parts, Arisaema balansae Engl. grass 34 parts, Radix heyneae trijugae 30 parts, Radix micheliae champacae 28 parts, Luo Xing grass 22 parts, Radix Caesalpiniae Radicis 22 parts, Fructus Fici Pumilae 18 parts, Flos Eriocauli 15 parts and Radix Luffae 11 parts.
The preparation method of described Chinese medicine composition, comprises the following steps:
(1) by adding the water of 8 times amount after Herba Asari, Folium seu Fructus Tarennae, Herba galinsogae parviflorae, Herba Arthraxonis Hispidi, Herba Cyathoclines purpureae, the Radix Angelicae Dahuricae, Luo Xingcao, Radix Caesalpiniae Radicis, Fructus Fici Pumilae and Flos Eriocauli mixing, extracting 2 hours, filtering, taking liquid; In remaining residue, add the water of 6 times amount again, extract 1 hour, filter, taking liquid; Merge twice medicinal liquid, be condensed into the thick paste of relative density 1.10-1.15 at 60 DEG C, drying under reduced pressure;
(2) Herba Bidentis Tripartitae, Arisaema balansae Engl. grass and Radix Luffae are put in pot to add with slow fire and propagandize hotly to surperficial buff, pulverize after fried dry, ground 200 order fine powders into powder, for subsequent use;
(3) get Fructus Canarii albi Fructus Canarii, add in fire and calcine, be placed in mortar and grind into powder, cross 180 order fine powders, for subsequent use;
(4) Radix heyneae trijugae and Radix micheliae champacae are added 10 times amount volumetric concentration 70% ethanol extraction three times, each 3 hours, filter, merging filtrate, placement is spent the night, and reclaiming ethanol and being concentrated into 60 DEG C of relative densities is that the dope of 1.12-1.15 is for subsequent use;
(5) dope mixing fine powder obtained to obtained for step (1) thick paste, step (2) and step (3) and step (4) obtained, makes capsule, is the active component of Chinese medicine composition of the present invention.
Embodiment 5
In the embodiment of the present invention, the application of a kind of Chinese medicine composition in preparation treatment viral influenza medicine, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 52 parts, Folium seu Fructus Tarennae 50 parts, Herba galinsogae parviflorae 48 parts, Herba Bidentis Tripartitae 45 parts, Herba Arthraxonis Hispidi 42 parts, Herba Cyathoclines purpureae 40 parts, Fructus Canarii albi 35 parts, the Radix Angelicae Dahuricae 35 parts, Arisaema balansae Engl. grass 30 parts, Radix heyneae trijugae 25 parts, Radix micheliae champacae 25 parts, Luo Xing grass 20 parts, Radix Caesalpiniae Radicis 20 parts, Fructus Fici Pumilae 15 parts, Flos Eriocauli 12 parts and Radix Luffae 8 parts.
The preparation method of described Chinese medicine composition, comprises the following steps:
(1) by adding the water of 8 times amount after Herba Asari, Folium seu Fructus Tarennae, Herba galinsogae parviflorae, Herba Arthraxonis Hispidi, Herba Cyathoclines purpureae, the Radix Angelicae Dahuricae, Luo Xingcao, Radix Caesalpiniae Radicis, Fructus Fici Pumilae and Flos Eriocauli mixing, extracting 3 hours, filtering, taking liquid; In remaining residue, add the water of 6 times amount again, extract 1 hour, filter, taking liquid; Merge twice medicinal liquid, be condensed into the thick paste of relative density 1.10-1.15 at 60 DEG C, drying under reduced pressure;
(2) Herba Bidentis Tripartitae, Arisaema balansae Engl. grass and Radix Luffae are put in pot to add with slow fire and propagandize hotly to surperficial buff, pulverize after fried dry, ground 200 order fine powders into powder, for subsequent use;
(3) get Fructus Canarii albi Fructus Canarii, add in fire and calcine, be placed in mortar and grind into powder, cross 180 order fine powders, for subsequent use;
(4) Radix heyneae trijugae and Radix micheliae champacae are added 10 times amount volumetric concentration 70% ethanol extraction three times, each 3 hours, filter, merging filtrate, placement is spent the night, and reclaiming ethanol and being concentrated into 60 DEG C of relative densities is that the dope of 1.12-1.15 is for subsequent use;
(5) dope mixing fine powder obtained to obtained for step (1) thick paste, step (2) and step (3) and step (4) obtained, makes granule, is the active component of Chinese medicine composition of the present invention.
Model case
Zhao, man, 28 years old, March in 2015,24 mouthfuls of head examined.Symptom: generate heat two days, body temperature 38.9 DEG C, has a stuffy nose and has dense nasal mucus, fear of cold, obviously thirsty, has sweating due to debility.Take the embodiment of the present invention 3 Chinese medicine composition continuously after two days, cold symptoms is eliminated, and physical recovery is healthy.
Pavilion, female, 32 years old, on April 15th, 2015, head examined.Symptom: flu a few days, take certain brand coldrex one week invalid, systemic is unable, and headache fever, used the embodiment of the present invention 3 Chinese medicine composition instead after three days, and cold symptoms is eliminated, physical recovery health.
Zhang, man, 11 years old, April in 2015,22 mouthfuls of head examined.Symptom: generate heat three days, body temperature 39.2 DEG C, has a stuffy nose and has nasal mucus clearly, without fear of cold, without obviously thirsty, lossless.Take the embodiment of the present invention 3 Chinese medicine composition continuously after two days, cold symptoms is eliminated, and physical recovery is healthy.
To those skilled in the art, obviously the invention is not restricted to the details of above-mentioned one exemplary embodiment, and when not deviating from spirit of the present invention or basic feature, the present invention can be realized in other specific forms.Therefore, no matter from which point, all should embodiment be regarded as exemplary, and be nonrestrictive, scope of the present invention is limited by claims instead of above-mentioned explanation, and all changes be therefore intended in the implication of the equivalency by dropping on claim and scope are included in the present invention.
In addition, be to be understood that, although this description is described according to embodiment, but not each embodiment only comprises an independently technical scheme, this narrating mode of description is only for clarity sake, those skilled in the art should by description integrally, and the technical scheme in each embodiment also through appropriately combined, can form other embodiments that it will be appreciated by those skilled in the art that.
Claims (4)
1. the application of Chinese medicine composition in preparation treatment viral influenza medicine, it is characterized in that, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 52-76 part, Folium seu Fructus Tarennae 50-74 part, Herba galinsogae parviflorae 48-72 part, Herba Bidentis Tripartitae 45-70 part, Herba Arthraxonis Hispidi 42-68 part, Herba Cyathoclines purpureae 40-65 part, Fructus Canarii albi 35-60 part, Radix Angelicae Dahuricae 35-60 part, Arisaema balansae Engl. grass 30-55 part, Radix heyneae trijugae 25-45 part, Radix micheliae champacae 25-40 part, Luo Xing grass 20-35 part, Radix Caesalpiniae Radicis 20-35 part, Fructus Fici Pumilae 15-30 part, Flos Eriocauli 12-24 part and Radix Luffae 8-20 part.
2. the application of Chinese medicine composition according to claim 1 in preparation treatment viral influenza medicine, it is characterized in that, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 70 parts, Folium seu Fructus Tarennae 68 parts, Herba galinsogae parviflorae 66 parts, Herba Bidentis Tripartitae 64 parts, Herba Arthraxonis Hispidi 61 parts, Herba Cyathoclines purpureae 58 parts, Fructus Canarii albi 54 parts, the Radix Angelicae Dahuricae 54 parts, Arisaema balansae Engl. grass 48 parts, Radix heyneae trijugae 40 parts, Radix micheliae champacae 36 parts, Luo Xing grass 30 parts, Radix Caesalpiniae Radicis 30 parts, Fructus Fici Pumilae 26 parts, Flos Eriocauli 21 parts and Radix Luffae 17 parts.
3. the application of Chinese medicine composition according to claim 1 in preparation treatment viral influenza medicine, it is characterized in that, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 64 parts, Folium seu Fructus Tarennae 62 parts, Herba galinsogae parviflorae 60 parts, Herba Bidentis Tripartitae 58 parts, Herba Arthraxonis Hispidi 54 parts, Herba Cyathoclines purpureae 52 parts, Fructus Canarii albi 48 parts, the Radix Angelicae Dahuricae 48 parts, Arisaema balansae Engl. grass 42 parts, Radix heyneae trijugae 35 parts, Radix micheliae champacae 32 parts, Luo Xing grass 26 parts, Radix Caesalpiniae Radicis 26 parts, Fructus Fici Pumilae 22 parts, Flos Eriocauli 18 parts and Radix Luffae 14 parts.
4. the application of Chinese medicine composition according to claim 1 in preparation treatment viral influenza medicine, it is characterized in that, according to parts by weight, the raw material making this drug composition active component is: Herba Asari 58 parts, Folium seu Fructus Tarennae 56 parts, Herba galinsogae parviflorae 54 parts, Herba Bidentis Tripartitae 52 parts, Herba Arthraxonis Hispidi 48 parts, Herba Cyathoclines purpureae 46 parts, Fructus Canarii albi 42 parts, the Radix Angelicae Dahuricae 42 parts, Arisaema balansae Engl. grass 34 parts, Radix heyneae trijugae 30 parts, Radix micheliae champacae 28 parts, Luo Xing grass 22 parts, Radix Caesalpiniae Radicis 22 parts, Fructus Fici Pumilae 18 parts, Flos Eriocauli 15 parts and Radix Luffae 11 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510540460.8A CN105169009A (en) | 2015-08-31 | 2015-08-31 | Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510540460.8A CN105169009A (en) | 2015-08-31 | 2015-08-31 | Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105169009A true CN105169009A (en) | 2015-12-23 |
Family
ID=54891758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510540460.8A Pending CN105169009A (en) | 2015-08-31 | 2015-08-31 | Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105169009A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491750A (en) * | 2016-12-21 | 2017-03-15 | 彭朝将 | A kind of Chinese medicine for treating acinetobacter |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1205223A (en) * | 1998-07-17 | 1999-01-20 | 宋栓牛 | Smelling medicine for prevention and treatment of cold and its prepn. method |
| CN1244422A (en) * | 1999-07-28 | 2000-02-16 | 李宏田 | Pain relieving ointment and its preparation |
| CN1448154A (en) * | 2002-04-02 | 2003-10-15 | 刘景君 | Medicine for treating exopathic disease and preparation process thereof |
| CN104189605A (en) * | 2014-09-20 | 2014-12-10 | 孟建国 | Traditional Chinese preparation for treating acute nasopharyngitis and preparation method thereof |
-
2015
- 2015-08-31 CN CN201510540460.8A patent/CN105169009A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1205223A (en) * | 1998-07-17 | 1999-01-20 | 宋栓牛 | Smelling medicine for prevention and treatment of cold and its prepn. method |
| CN1244422A (en) * | 1999-07-28 | 2000-02-16 | 李宏田 | Pain relieving ointment and its preparation |
| CN1448154A (en) * | 2002-04-02 | 2003-10-15 | 刘景君 | Medicine for treating exopathic disease and preparation process thereof |
| CN104189605A (en) * | 2014-09-20 | 2014-12-10 | 孟建国 | Traditional Chinese preparation for treating acute nasopharyngitis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 桂卉等: "HPLC考察川芎茶调颗粒制备中川芎嗪的动态变化", 《中成药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491750A (en) * | 2016-12-21 | 2017-03-15 | 彭朝将 | A kind of Chinese medicine for treating acinetobacter |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021155751A1 (en) | Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof | |
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN103099948A (en) | Pharmaceutical composition for treating pharyngitis and preparation method | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN101564458A (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| CN103316086B (en) | Tibetan medicine for treating influenza and preparation method thereof | |
| CN104888058A (en) | Antibacterial and anti-inflammation external preparation and method for preparing same | |
| CN101138613A (en) | Traditional Chinese medicine for treating acute bronchitis of children | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN105169009A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza | |
| CN101406522B (en) | Use of pharmaceutical composition in preparing medicament for treating viral influenza | |
| CN117731680A (en) | Pharmaceutical composition for treating infantile diarrhea, and preparation method and application thereof | |
| CN105213615A (en) | Compound Solanum Nigrum Pianomide | |
| CN104623379B (en) | A kind of pharmaceutical composition for treating children's hand-foot-mouth disease | |
| CN100367977C (en) | A kind of Herba Resurrection extract, its extraction method and preparation | |
| CN101549051B (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof | |
| CN100502916C (en) | A kind of antiviral pharmaceutical composition and preparation method thereof | |
| CN104587051A (en) | Application of pharmaceutical composition in preparation of medicine for treating viral influenza | |
| CN104547247A (en) | Applications of pharmaceutical composition in preparation of drug for treating viral cold | |
| CN104984131A (en) | Application of traditional Chinese medicine composition in preparation of drugs for treating influenza | |
| CN102233026B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN104586924B (en) | Redback christmashush root extract and preparation method and preparation treatment hepatic fibrosis medicines application | |
| CN102727624B (en) | New application of enteritis peaching composition on treatment of chronic prostatitis | |
| CN103028064A (en) | Pharmaceutical composition for treating urinary tract infection and preparation method | |
| CN104173481B (en) | A kind of Chinese medicine composition of resistance prostatitis disease and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151223 |